Safety and Efficacy Assessment for the Temporary Facial Skin Tightening Improvement Effect Using the Monopolar Radiofrequency Device

This is a prospective, single-center, comparative, randomized, evaluator-blinded, superiority, confirmatory clinical trial designed to demonstrate the temporary improvement in skin elasticity and to evaluate the safety of an investigational medical device using radiofrequency current when applied to the face (both cheeks), compared with a control device.

Inclusion criteria

• Participants who are at least 19 years old and under 65 years of age as of the date of written informed consent.
• Participants whose average Cutometer R7 value for both checks is ≤0.6.
• Participants who consent to photographic documentation for verification of skin type(Fitzpatrick skin scale) and evaluation of treatment efficacy.
• Participants who agree to refrain from receiving any procedures or therapies that could influence skin elasticity improvement throughout the study period.
• Participants who agree to employ medically acceptable contraception for up to 4 weeks following the end of the study
• Participants who have adequately understood the objectives and procedures of the clinical trial, voluntarily consent in writing to participate, and are able to complete the study as required.

Exclusion criteria

• Participants who have any medical or dermatologic condition at the investigational medical device application area that may influence the conduct or results of the study.
• Participants who have scars or open lesions at the investigational medical device application area that may influence the conduct or results of the study.
• Participants who have metal stents or implants at the investigational medical device application area.
• Participants with severe solar elastosis.
• Participants judged by the investigator to have excessive facial subcutaneous fat requiring surgical intervention.
• Participants with a history of anaphylaxis or severe complex allergic reactions.
• Participants with a history of or predisposition to hypertrophic scars or keloid formation.
• Participants with a history of adverse reactions to EMLA cream or local anesthetics (However, this criterion does not apply to participants who will not use anesthetics such as EMLA cream).
• Participants who have clinically significant disorders in the cardiovascular, gastrointestinal, respiratory, endocrine, or central nervous system that are not controlled by medication, or who have a history of or are currently receiving treatment for psychiatric disorders that may significantly affect this study.
• Participants with active herpes virus infection or autoimmune disease.
• Participants currently diagnosed with diabetes mellitus or epilepsy.
• Participants taking more than 100 mg of aspirin or aspirin-containing medication per day.
• Participants with bleeding disorders or blood coagulation-related diseases, such as thrombosis.
• Participants who have received Botox or filler injections at the investigational medical device application area* within 24 weeks prior to screening (*Investigational medical device application area: For participants undergoing facial (both cheeks) treatment - Mid-face (eyes to upper lip), Lower-face (lower lip to chin)) (However, if Botox or fillers were injected into the face but not within the application area, at least 12 weeks must have elapsed since the procedure).
• Participants who have undergone laser or light therapy at the investigational medical device application area within 24 weeks prior to screening.
• Participants who have undergone surgical or non-surgical treatments, such as deep chemical peels or liposuction, at the investigational medical device application area within 24 weeks prior to screening.
• Participants who have used topical agents (steroids, retinoids; limited to medicinal products, excluding cosmetics) at the investigational medical device application area within 4 weeks prior to screening, or who plan to continue use during the study.
• Participants who have smoked 100 or more cigarettes in their lifetime (However, those who have abstained from smoking for 24 weeks prior to screening are eligible for enrollment).
• Participants who are currently participating in another interventional clinical trial within 4 weeks prior to screening, or who plan to participate in another interventional clinical trial during this study.
• Pregnant or lactating women.
• Participants who are otherwise deemed unsuitable for participation in this study by the investigator.